Wise Analytics Group uses data to help companies, consumers and brands make better connections and more benefitial choices. They are a leader in terms of media analytics in the beauty sector, using a range of tools, technology and experience to create a product, market and consumer insight. Wise Analytics group have clients such as L'Oreal and Estee lauder. They are now looking to expand into other locations.
days to go:
Expired
investment:
Withheld
SkiBro is a leading business-to-customer (B2B) Software as a Service (SaaS) platform that aspires to become a contender in the €2 billion ski lessons market. The platform has onboarded 8,000 ski schools and 150,000 ski instructors to date. SkiBro's marketplace encompasses 350 resorts in 7 countries across Europe and North America, with over 6,000 ski instruction products. SkiBro intends to expand into ski hire. The platform has 350 independent ski instructors (250 last year) and 400+ ski schools, with notable ones including ESF La Plagne, ESF Courchevel, Evolution2 (France), Skischule Alberg (Austria), and Ski and Snowboard School Courmayeur (Italy). The company claims that despite COVID-19 hampering business in March 2020, the platform hosted 8.467 lesson bookings worth €1.35 million, recording a 500% YoY growth with an average booking value of €453. SkiBro is seeking £1.5 million of equity funding to accelerate company growth and deliver profitability in 2023-2024.
days to go:
Expired
investment:
£749,825
JiveBird allows users to create and send a greetings package that consists of a personal voice message, music, eCard, a photo or selfie, and a gift to their loved ones or acquaintances. The company asserts that its package can be sent at the last minute or in advance. Jivebird claims that for the millions of people who send greetings and gifts every year, its portal provides a personal, cheaper, and convenient way to send greetings. Jivebird argues that it has no direct competitors. Its exit strategy is to sell the company when it achieves the growth metrics in the business plan, projected to be within five years of consumer launch.
days to go:
Expired
investment:
Withheld
Zap and Go have created ultra fast technology for cordless and hand held devices by using Carbon-Ion technology which result in ultra-fast charging, taking 5 minutes or less. The technology is part derived from Oxford University and in part developed independently by Zap&Go's own scientists.
days to go:
Expired
investment:
£1,353,551
ARROE Limited is planning on creating an ecosystem of software and hardware products to eliminate the charging problem. The company has made the first universal laptop charging solution by joining software and hardware. Since 2016, the business and products of the company have evolved enormously, but the key focus of the company is to free people from the wall socket. It will sell their products through three channels: B2C (Website), B2B and B2C (Brand partners). The ARROE application will become the virtual assistant for power management.
days to go:
Expired
investment:
£360,000
VoxSmart is a global mobile technology company focused on achieving compliance in a very heavy regulated industries such as finance and banking. VoxSmart software is embedded on the mobile device and allows the capturing and recording of all communications on that device
days to go:
Expired
investment:
£3,857,500
SilkFred is a curated online marketplace for over 200 independent fashion brands. It’s a destination for customers seeking to differentiate their wardrobes. SilkFred cuts through the noise of online shopping and provides a central destination for female shoppers to find affordable pieces that their friends won’t have (and will love!). Having cultivated a cult social media status and attracted a growing number of loyal shoppers and brands, SilkFred is now ready to scale its business model rapidly.
www.silkfred.com
days to go:
Expired
investment:
£906,630
Rockabox is a global leader in programmatic technology for rich media marketing and is at the forefront of a revolution that is occurring in the $118 billion online advertising industry.
days to go:
Expired
investment:
£4,274,422
RightIndem is a white-label insurance software platform designed to deliver fast claims to claimants on its portal. The company develops and sells its own proprietary cloud-based digital claim process management software ‘as a service’ to the global insurance market. Insurtech is a vast market and attracts large amounts of investment, with $4.36 billion invested in the first three quarters of 2019. Till date, it has contracted clients such as Axa XL, Archipelago, NN Belgium, NN Netherlands, and Mapfre, with engagements at various levels of implementation and progress in the UK, Italy, Peru, US, and South Africa. They have also earned regard for automating claims processes form some of the world’s largest insurance organizations allowing for the settlement of low to mid-value claims within hours instead of days or months. With the proceeds, the company will connect operating expenses to the point where client revenues from claim volumes match operating costs.
days to go:
Expired
investment:
£200,001
Novai is a UK biotechnology company, developing and commercialising transformational technology in ophthalmology. The company's initial focus is on ophthalmic disorders such as glaucoma and AMD (Age-related Macular Degeneration). Novai argues that current clinical endpoints lack early disease biomarkers to objectively detect and measure cell health and response to treatment in the retina. Novai asserts that its proprietary biological marker, DARC (Detection of Apoptosis in Retinal Cells), combined with its bespoke and patented Artificial Intelligence (AI) aided algorithm, allows, for the first time in vivo, identification of cellular-level disease activity in the retina. Novai stresses that DARC can also predict disease progression, allowing for enrichment of clinical trial cohorts. The company anticipates an exit via licensing of its biomarker business to a Contract Research Organisation (CRO), an Initial Public Offering (IPO) following a successful phase 3 trial of the diagnostic platform, or trade sale to a strategic pharmaceutical company.
days to go:
Expired
investment:
£1,314,967
